Levicept Announces Attendance at Major Healthcare Conferences in Q4

SANDWICH, United Kingdom, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a clinical-stage biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), is pleased to announce that it will be presenting data at forthcoming major international healthcare conferences alongside its attendance at a major global banking conference in Q4 2026.

Results from Levicept’s Phase II trial of its LEVI-04 (ClinicalTrials.gov ID: NCT05618782) including new analyses will be presented at:

International Association for the Study of Pain, IASP World Congress on Pain 2026 (Bangkok, 26-30 October)
American College of Rheumatology, annual ACR Convergence 2026 (Orlando, 6-11 November)

As previously announced, the Levicept team will also be attending the Jefferies 2026 Global Healthcare Conference (London, 16-19 November) where Levicept’s CEO Eliot Forster, CSO Simon Westbrook and CFO Darlene Deptula-Hicks will be available for meetings.

Levicept is advancing a new non-opioid analgesic for OA, a condition which affects hundreds of millions of patients worldwide. Results from Levicept’s Phase II trial of its LEVI-04 (ClinicalTrials.gov ID: NCT05618782) were published in The Lancetⁱ and demonstrated significant symptom control. LEVI-04 was well tolerated in this study. Previously, Levicept has presented analysis suggesting LEVI-04 may have the potential to modify the disease progression of OA. To Levicept’s knowledge, this is the first time a molecule has demonstrated analgesia and potential disease modification in a clinical study in OA. If approved, LEVI-04 would be the first new systemic treatment for OA in over two decades.

Conaghan P, et al. LANCET Volume 407, Issue 10535, 28 March–3 April 2026, Pages 1237-1248

Levicept
Eliot Forster, CEO - eliot@levicept.com

Media Enquiries
Charles Consultants
Sue Charles - Sue@charles-consultants.com +44 (0)7968 726585
Chris Gardner - Chris@CGComms.onmicrosoft.com +44 (0)7956 031077

About Levicept – www.levicept.com

Levicept is a clinical stage biotechnology company developing a first-in-class non-opioid analgesic, LEVI-04, to treat the symptoms and disease of osteoarthritis. LEVI-04 is a biomimic of the neurotrophin chaperone protein p75NTR, designed to restore neurotrophin balance. LEVI-04 inhibits NT-3 while maintaining physiological activity of the remaining three neurotrophins including NGF. LEVI-04 has completed a Phase II clinical trial in more than 500 patients. It demonstrated significant symptom control and was well tolerated in this study. The data further suggest LEVI-04 may have the potential to modify the disease progression of OA. LEVI-04 was discovered by Levicept’s founder, Simon Westbrook. The company’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.